Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00203970|
Recruitment Status : Active, not recruiting
First Posted : September 20, 2005
Last Update Posted : August 30, 2017
|Condition or disease||Intervention/treatment|
The design of our study is retrospective in nature. We are interested primarily in the use of LMWH in patients admitted to the general medicine services between January 1, 1997 and February 1, 2001 with a primary and secondary diagnosis related to Venous Thromboembolism, including specific ICD-9 codes.
Using a data abstraction form, we gather the following information: 1) patient demographics, 2) identity of the attending, resident, and interns caring for the patient, 3) whether the patient had any absolute or relative contraindications for receiving LMWH, as delineated by the DVT critical pathway, including insurance status and 4)how the patient was treated for his/her condition. To examine whether the identity of the primary care physician affects whether LMWH is given, we also collect the name of the primary care physician if it is listed on the chart.
|Study Type :||Observational|
|Actual Enrollment :||645 participants|
|Official Title:||Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services|
|Study Start Date :||February 2001|
|Actual Primary Completion Date :||March 2001|
|Estimated Study Completion Date :||January 2019|
- retrospective chart review to determine how patients with deep venous thromboses or pulmonary emboli were treated when hospitalized on the medicine services [ Time Frame: June 1997 to December 2000 ]Using the data abstraction form, we gathered the following information: 1) patient demographics, 2) the identity of the attending, resident, and intern caring for the patient, 3) whether the patient had any absolute or relative contraindications for receiving LMWH, as delineated by the DVT critical pathway, including insurance status and 4) how the patient was treated for his/her condition.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00203970
|United States, Illinois|
|The University of Chicago|
|Chicago, Illinois, United States, 60637|
|Principal Investigator:||David Meltzer, M.D., Ph.D.||University of Chicago|